前列腺癌组织中RBMS1的表达与患者临床病理特征及预后的关系

doi:10.3969/j.issn.1006-6233.2025.02.019

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1508 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore the relationship between the expression of RNA Binding Motif Single-Strand Interacting Protein 1 (RBMS1) in prostate cancer (PCa) tissue and the clinical pathological features and prognosis of patients. Methods: A total of 135 PCa patients admitted to our hospital from December 2018 to December 2020 were selected. Immunohistochemistry was used to detect the expression of RBMS1. The relationship between RBMS1 expression and prognosis in PCa patients was analyzed using the Kaplan-Meier method. The factors affecting the prognosis of PCa patients were analyzed using Cox regression. Results: Compared with adjacent cancer-free tissue, the positive expression rate of RBMS1 in PCa tissue was significantly lower (27.41% vs 68.89%, χ² = 46.523, P<0.05). The expression of RBMS1 in PCa tissue was significantly different among TNM stage, Gleason score, and lymph node metastasis (P<0.05). Patients with positive RBMS1 expression in PCa tissue had a significantly higher 3-year survival rate compared to those with negative RBMS1 expression (Log Rank χ² = 4.583, P = 0.032). Cox regression analysis revealed that negative RBMS1 expression, TNM stage III, lymph node metastasis, and Gleason score >7 were risk factors for poor prognosis in PCa patients (P<0.05). Conclusion: The positive expression rate of RBMS1 in PCa tissue is significantly lower and is associated with the clinical pathological features and prognosis of patients.

Key words： RBMS1 Prostate cancer Clinical pathological features Prognosis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Tao
	LIAO Duwu
	YANG Jianbo
	et al

Cite this article:

ZHANG Tao,LIAO Duwu,YANG Jianbo, et al. Expression of RBMS1 in Prostate Cancer Tissue and Its Relationship with Clinical Pathological Features and Prognosis of Patients[J]. HeBei Med, 2025, 31(2): 286-290.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2025.02.019 OR http://www.hbyxzzs.cn/EN/Y2025/V31/I2/286

[1] 李旭瑜,张玉,张海建,等.前列腺癌组织中长链非编码RNA OSTN-AS1、微RNA-1207-3p的表达与临床病理参数和预后的关系[J].中国医药导报,2023,20(29):107-111.
[2] Boehm BE,York ME,Petrovics G,et al.Biomarkers of aggressive prostate cancer at diagnosis[J].Int Mol Sci,2023,24(3):2185-2203.
[3] 李星,曾晓勇.中国前列腺癌流行病学研究进展[J].肿瘤防治研究,2021,48(1):98-102.
[4] Yu J,Culbertson B,Asgharian H,et al.RBMS1 suppresses colon cancer metastasis through targeted stabilization of its mRNA regulon[J].Cancer Discov,2020,10(9):1410-1423.
[5] 房志学,叶凡,周宇帆,等.胃腺癌组织RBMS1、AKAP12表达变化及其临床意义[J].山东医药,2023,63(13):20-23,39.
[6] Mansouri N,Msakni I,Gargouri F,et al.Evaluation of concordance of gleason score between prostate biopsy and radical prostatectomy[J].Tunis Med,2018,96(7):430-436.
[7] 王蔚,苏嘉明,袁东波,等.微管相关蛋白1A在前列腺癌中的表达与其临床特征的关系[J].首都医科大学学报,2019,40(1):65-71.
[8] 严志伟,李彦泽,杜洋,等.前列腺癌诊断相关生物标志物的研究进展[J].肿瘤学杂志,2023,29(7):611-616.
[9] Zhai H,Zhong S,Wu R,et al.Suppressing circIDE/miR-19b-3p/RBMS1 axis exhibits promoting-tumour activity through upregulating GPX4 to diminish ferroptosis in hepatocellular carcinoma[J].Epigenetics,2023,18(1):2-18.
[10] Dankert JT,Wiesehofer M,Wach S,et al.Loss of RBMS1 as a regulatory target of miR-106b influences cell growth,gap closing and colony forming in prostate carcinoma[J].Sci Rep,2020,10(1):1-12.
[11] Zhang C,Wang S,Chao F,et al.The short inverted repeats-induced circEXOC6B inhibits prostate cancer metastasis by enhancing the binding of RBMS1 and HuR[J].Mol Ther,2023,31(6):1705-1721.
[12] Aggarwal P,Bhavesh N S.Hinge like domain motion facilitates human RBMS1 protein binding to proto-oncogene c-myc promoter[J].Nucleic Acids Res.2021,49(10):5943-5955.
[13] 张瑜,徐飞.前列腺癌患者生存情况随访调查及预后影响因素[J].中国卫生工程学,2021,20(6):965-966.